Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors Rosen, L., LoRusso, P., Ma, W., Goldman, J., Weise, A., Colevas, A., Adjei, A., Yazji, S., Shen, A., Johnston, S., Gates, M. R., Jones, C., Musib, L., De Crespigny, A., Chan, I., Sikic, B. AMER ASSOC CANCER RESEARCH. 2011
View details for DOI 10.1158/1538-7445.AM2011-4716
View details for Web of Science ID 000209701404368